165 related articles for article (PubMed ID: 19617848)
41. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy.
Viganò A; Zuccotti GV; Pacei M; Erba P; Castelletti E; Giacomet V; Amendola A; Pariani E; Tanzi E; Clerici M
J Acquir Immune Defic Syndr; 2008 Jul; 48(3):289-96. PubMed ID: 18545155
[TBL] [Abstract][Full Text] [Related]
42. Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy.
Weinberg A; Dickover R; Britto P; Hu C; Patterson-Bartlett J; Kraimer J; Gutzman H; Shearer WT; Rathore M; McKinney R;
AIDS; 2008 Nov; 22(17):2267-77. PubMed ID: 18981766
[TBL] [Abstract][Full Text] [Related]
43. Serological responses to revaccination with hepatitis A virus (HAV) vaccines among HIV-positive individuals whose anti-HAV antibody waned after primary vaccination.
Chen GJ; Sun HY; Lin KY; Cheng A; Huang YC; Hsieh SM; Sheng WH; Liu WC; Hung CC; Chang SC
Liver Int; 2018 Jul; 38(7):1198-1205. PubMed ID: 29240985
[TBL] [Abstract][Full Text] [Related]
44. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
45. Changes in hepatitis A virus seroepidemiology in HIV-infected Brazilian patients.
Aloise R; de Almeida AJ; Sion FS; Morais-de-Sá CA; Gaspar AM; de Paula VS
Int J STD AIDS; 2008 May; 19(5):321-6. PubMed ID: 18482962
[TBL] [Abstract][Full Text] [Related]
46. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
[TBL] [Abstract][Full Text] [Related]
47. Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up.
Sharapov UM; Bulkow LR; Negus SE; Spradling PR; Homan C; Drobeniuc J; Bruce M; Kamili S; Hu DJ; McMahon BJ
Hepatology; 2012 Aug; 56(2):516-22. PubMed ID: 22371069
[TBL] [Abstract][Full Text] [Related]
48. The Humoral Immune Response to BNT162b2 Vaccine Is Associated With Circulating CD19+ B Lymphocytes and the Naïve CD45RA to Memory CD45RO CD4+ T Helper Cells Ratio in Hemodialysis Patients and Kidney Transplant Recipients.
Duni A; Markopoulos GS; Mallioras I; Pappas H; Pappas E; Koutlas V; Tzalavra E; Baxevanos G; Priska S; Gartzonika K; Mitsis M; Dounousi E
Front Immunol; 2021; 12():760249. PubMed ID: 34925330
[TBL] [Abstract][Full Text] [Related]
49. Immunogenicity and tolerability of hepatitis A vaccine in HIV-infected children.
Gouvea AF; De Moraes-Pinto MI; Ono E; Dinelli MI; Machado DM; Weckx LY; Succi RC
Clin Infect Dis; 2005 Aug; 41(4):544-8. PubMed ID: 16028166
[TBL] [Abstract][Full Text] [Related]
50. Anti-Tat immunity defines CD4
Tripiciano A; Picconi O; Moretti S; Sgadari C; Cafaro A; Francavilla V; Arancio A; Paniccia G; Campagna M; Pavone-Cossut MR; Sighinolfi L; Latini A; Mercurio VS; Pietro MD; Castelli F; Saracino A; Mussini C; Perri GD; Galli M; Nozza S; Ensoli F; Monini P; Ensoli B
EBioMedicine; 2021 Apr; 66():103306. PubMed ID: 33839064
[TBL] [Abstract][Full Text] [Related]
51. [Prevalence of hepatitis A antibody among population covered by different hepatitis A immunization strategies in Shandong Province, 2015, China].
Kong Q; Yan BY; Lyu JJ; Feng Y; Liu JY; Song LZ; Xu Q; Zhang L; Xu AQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Jun; 51(6):480-483. PubMed ID: 28592089
[No Abstract] [Full Text] [Related]
52. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
Piriou E; Jansen CA; van Dort K; De Cuyper I; Nanlohy NM; Lange JM; van Oers MH; Miedema F; van Baarle D
J Immunol; 2005 Aug; 175(3):2010-7. PubMed ID: 16034146
[TBL] [Abstract][Full Text] [Related]
53. Low immune response rate of HIV-infected patients to a single injection of hepatitis A vaccine.
Noël L; Tubiana R; Simon A; Valantin MA; Palich R; Blanc C; Katlama C; Marcelin AG; Calvez V; Todesco E
Infect Dis Now; 2021 Feb; 51(1):94-96. PubMed ID: 33022294
[TBL] [Abstract][Full Text] [Related]
54. Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study.
Sullivan SG; Hirsch HH; Franceschi S; Steffen I; Amari EB; Mueller NJ; Magouras I; Biggar RJ; Rickenbach M; Clifford GM;
AIDS; 2010 Sep; 24(14):2245-52. PubMed ID: 20543658
[TBL] [Abstract][Full Text] [Related]
55. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy.
Moir S; Buckner CM; Ho J; Wang W; Chen J; Waldner AJ; Posada JG; Kardava L; O'Shea MA; Kottilil S; Chun TW; Proschan MA; Fauci AS
Blood; 2010 Dec; 116(25):5571-9. PubMed ID: 20837780
[TBL] [Abstract][Full Text] [Related]
56. Improved cell mediated immune responses after successful re-vaccination of non-responders to the hepatitis B virus surface antigen (HBsAg) vaccine using the combined hepatitis A and B vaccine.
Nyström J; Cardell K; Björnsdottir TB; Fryden A; Hultgren C; Sällberg M
Vaccine; 2008 Nov; 26(47):5967-72. PubMed ID: 18804140
[TBL] [Abstract][Full Text] [Related]
57. Antibody persistence and immune memory in adults, 15 years after a three-dose schedule of a combined hepatitis A and B vaccine.
Van Damme P; Leroux-Roels G; Crasta P; Messier M; Jacquet JM; Van Herck K
J Med Virol; 2012 Jan; 84(1):11-7. PubMed ID: 22052690
[TBL] [Abstract][Full Text] [Related]
58. Immune response to hepatitis A vaccination in HIV-infected men in Greece.
Kourkounti S; Mavrianou N; Paparizos VA; Kyriakis K; Hatzivassiliou M; Kordosis T; Katsambas A
Int J STD AIDS; 2012 Jul; 23(7):464-7. PubMed ID: 22843998
[TBL] [Abstract][Full Text] [Related]
59. Modeling the long-term persistence of hepatitis A antibody after a two-dose vaccination schedule in Argentinean children.
López EL; Contrini MM; Mistchenko A; Kieffer A; Baggaley RF; Di Tanna GL; Desai K; Rasuli A; Armoni J
Pediatr Infect Dis J; 2015 Apr; 34(4):417-25. PubMed ID: 25764099
[TBL] [Abstract][Full Text] [Related]
60. Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine.
Van Herck K; Crasta PD; Messier M; Hardt K; Van Damme P
Hum Vaccin Immunother; 2012 Mar; 8(3):323-7. PubMed ID: 22327499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
